Janus Henderson Group PLC Biotechnology

Janus Henderson Group PLC

$194 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ARGX Argenx Se	$42.4B	$1.41 Billion 0.73% of portfolio	2,565,399	Q2 2025 Added 19.71%
VRTX Vertex Pharmaceuticals Inc	$102B	$1.17 Billion 0.6% of portfolio	2,619,534	Q2 2025 Reduced 4.67%
ASND Ascendis Pharma A/S	$11.3B	$764 Million 0.39% of portfolio	4,427,792	Q2 2025 Reduced 1.32%
MDGL Madrigal Pharmaceuticals, Inc.	$7.67B	$663 Million 0.34% of portfolio	2,191,753	Q2 2025 Reduced 0.64%
VRNA Verona Pharma PLC	$6.48B	$580 Million 0.3% of portfolio	6,134,405	Q2 2025 Added 11.19%
PCVX Vaxcyte, Inc.	$1.94B	$478 Million 0.25% of portfolio	14,691,344	Q2 2025 Added 24.87%
BBIO Bridge Bio Pharma, Inc.	$7.93B	$401 Million 0.21% of portfolio	9,276,532	Q2 2025 Added 29.35%
RVMD Revolution Medicines, Inc.	$3.59B	$390 Million 0.2% of portfolio	10,590,727	Q2 2025 Added 3.93%
AKRO Akero Therapeutics, Inc.	$2.07B	$360 Million 0.19% of portfolio	6,738,556	Q2 2025 Reduced 4.67%
RNA Avidity Biosciences, Inc.	$2.43B	$306 Million 0.16% of portfolio	10,777,317	Q2 2025 Reduced 5.68%
MIRM Mirum Pharmaceuticals, Inc.	$2.86B	$266 Million 0.14% of portfolio	5,236,277	Q2 2025 Added 9.86%
INSM Insmed Inc	$19.9B	$231 Million 0.12% of portfolio	2,293,142	Q2 2025 Added 48.38%
ETNB 89bio, Inc.	$399M	$204 Million 0.11% of portfolio	20,788,363	Q2 2025 Added 1.59%
PTCT Ptc Therapeutics, Inc.	$4.18B	$155 Million 0.08% of portfolio	3,175,015	Q2 2025 Added 8.86%
TVTX Travere Therapeutics, Inc.	$1.39B	$141 Million 0.07% of portfolio	9,541,270	Q2 2025 Added 26.73%
NUVL Nuvalent, Inc.	$3.38B	$136 Million 0.07% of portfolio	1,782,581	Q2 2025 Added 36.05%
IDYA Ideaya Biosciences, Inc.	$1.19B	$130 Million 0.07% of portfolio	6,206,238	Q2 2025 Reduced 3.05%
LGND Ligand Pharmaceuticals Inc	$2.79B	$121 Million 0.06% of portfolio	1,060,734	Q2 2025 Added 3.23%
XENE Xenon Pharmaceuticals Inc.	$2.34B	$112 Million 0.06% of portfolio	3,577,735	Q2 2025 Added 7.6%
JANX Janux Therapeutics, Inc.	$991M	$103 Million 0.05% of portfolio	4,460,332	Q2 2025 Reduced 3.0%
CRNX Crinetics Pharmaceuticals, Inc.	$1.96B	$98.1 Million 0.05% of portfolio	3,410,320	Q2 2025 Reduced 0.41%
DYN Dyne Therapeutics, Inc.	$686M	$89.8 Million 0.05% of portfolio	9,437,962	Q2 2025 Reduced 8.84%
RYTM Rhythm Pharmaceuticals, Inc.	$5.65B	$89.2 Million 0.05% of portfolio	1,411,902	Q2 2025 Reduced 14.71%
SRRK Scholar Rock Holding Corp	$1.61B	$86.8 Million 0.04% of portfolio	2,450,286	Q2 2025 Added 46.71%
CNTA Centessa Pharmaceuticals PLC	$1.97B	$85.8 Million 0.04% of portfolio	6,532,768	Q2 2025 Added 10.3%
UTHR United Therapeutics Corp	$18.4B	$80.9 Million 0.04% of portfolio	281,523	Q2 2025 Added 47.09%
ZLAB Zai Lab LTD	$3.08B	$76.9 Million 0.04% of portfolio	2,197,860	Q2 2025 Reduced 42.37%
LEGN Legend Biotech Corp	$5.73B	$74.3 Million 0.04% of portfolio	2,092,732	Q2 2025 Added 1.7%
TARS Tarsus Pharmaceuticals, Inc.	$1.51B	$73.2 Million 0.04% of portfolio	1,806,947	Q2 2025 Added 252.26%
EWTX Edgewise Therapeutics, Inc.	$932M	$72.1 Million 0.04% of portfolio	5,503,349	Q2 2025 Added 4.19%
ACLX Arcellx, Inc.	$3.16B	$67.4 Million 0.03% of portfolio	1,023,582	Q2 2025 Reduced 32.24%
ARDX Ardelyx, Inc.	$1.01B	$59 Million 0.03% of portfolio	15,057,940	Q2 2025 Reduced 39.71%
ALNY Alnylam Pharmaceuticals, Inc.	$59.3B	$49.1 Million 0.03% of portfolio	150,421	Q2 2025 Reduced 17.19%
MREO Mereo Biopharma Group PLC	$221M	$47.9 Million 0.02% of portfolio	17,688,592	Q2 2025 Reduced 22.2%
HALO Halozyme Therapeutics, Inc.	$10.6B	$47.4 Million 0.02% of portfolio	910,394	Q2 2025 Added 27.38%
MRUS Merus N.V.	$3.14B	$43.6 Million 0.02% of portfolio	829,558	Q2 2025 Added 117.27%
BPMC Blueprint Medicines Corp	$7.73B	$34.5 Million 0.02% of portfolio	268,928	Q2 2025 Added 835.43%
ARQT Arcutis Biotherapeutics, Inc.	$1.08B	$31.7 Million 0.02% of portfolio	2,263,960	Q2 2025 Added 4,204.11%
TYRA Tyra Biosciences, Inc.	$496M	$27.3 Million 0.01% of portfolio	2,856,290	Q2 2025 Added 6.05%
PTGX Protagonist Therapeutics, Inc	$2.86B	$24.7 Million 0.01% of portfolio	446,828	Q2 2025 Added 1,982.73%
EXEL Exelixis, Inc.	$12.3B	$22 Million 0.01% of portfolio	499,654	Q2 2025 Added 169.54%
COGT Cogent Biosciences, Inc.	$843M	$20.6 Million 0.01% of portfolio	2,873,053	Q2 2025 Added 9,782.2%
LQDA Liquidia Corp	$1.79B	$20.3 Million 0.01% of portfolio	1,631,948	Q2 2025 Reduced 0.45%
SWTX Spring Works Therapeutics, Inc.	$2.93B	$18 Million 0.01% of portfolio	383,701	Q2 2025 Added 1,319.8%
CPRX Catalyst Pharmaceuticals, Inc.	$2.06B	$16.3 Million 0.01% of portfolio	751,562	Q2 2025 Added 134.99%
FOLD Amicus Therapeutics, Inc.	$2.21B	$15.8 Million 0.01% of portfolio	2,753,710	Q2 2025 Reduced 17.09%
OLMA Olema Pharmaceuticals, Inc.	$301M	$12.9 Million 0.01% of portfolio	3,022,784	Q2 2025 New
TARA Protara Therapeutics, Inc.	$34.7M	$12.4 Million 0.01% of portfolio	4,102,620	Q2 2025 Added 8.3%
TRDA Entrada Therapeutics, Inc.	$161M	$10.2 Million 0.01% of portfolio	1,521,281	Q2 2025 Reduced 28.3%
IMNM Immunome Inc.	$108M	$9.68 Million 0.0% of portfolio	1,040,414	Q2 2025 Reduced 50.18%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.